Pulmonary Vasodilator Therapy in the NICU: Inhaled Nitric Oxide, Sildenafil, and Other Pulmonary Vasodilating Agents

Nicolas F M Porta, Robin H Steinhorn

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

The perinatal transition from fetal to extrauterine life requires a dramatic change in the circulatory pattern as the organ of gas exchange switches from the placenta to the lungs. Pulmonary hypertension can occur during early newborn life, and present as early respiratory failure or as a complication of more chronic diseases, such as bronchopulmonary dysplasia. The most effective pharmacotherapeutic strategies for infants with persistent pulmonary hypertension of the newborn are directed at selective reduction of pulmonary vascular resistance. This article discusses currently available therapies for pulmonary hypertension, their biologic rationales, and evidence for their clinical effectiveness.

Original languageEnglish (US)
Pages (from-to)149-164
Number of pages16
JournalClinics in Perinatology
Volume39
Issue number1
DOIs
StatePublished - Mar 2012
Externally publishedYes

Fingerprint

Vasodilator Agents
Pulmonary Hypertension
Nitric Oxide
Persistent Fetal Circulation Syndrome
Bronchopulmonary Dysplasia
Lung
Respiratory Insufficiency
Vascular Resistance
Placenta
Chronic Disease
Gases
Newborn Infant
Therapeutics
Sildenafil Citrate

Keywords

  • Phosphodiesterase
  • Prostacyclin
  • Pulmonary hypertension
  • Pulmonary vasculature
  • Vasodilator

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Pulmonary Vasodilator Therapy in the NICU : Inhaled Nitric Oxide, Sildenafil, and Other Pulmonary Vasodilating Agents. / Porta, Nicolas F M; Steinhorn, Robin H.

In: Clinics in Perinatology, Vol. 39, No. 1, 03.2012, p. 149-164.

Research output: Contribution to journalArticle

@article{d830bf671b13486c9bf676f2f4f311a1,
title = "Pulmonary Vasodilator Therapy in the NICU: Inhaled Nitric Oxide, Sildenafil, and Other Pulmonary Vasodilating Agents",
abstract = "The perinatal transition from fetal to extrauterine life requires a dramatic change in the circulatory pattern as the organ of gas exchange switches from the placenta to the lungs. Pulmonary hypertension can occur during early newborn life, and present as early respiratory failure or as a complication of more chronic diseases, such as bronchopulmonary dysplasia. The most effective pharmacotherapeutic strategies for infants with persistent pulmonary hypertension of the newborn are directed at selective reduction of pulmonary vascular resistance. This article discusses currently available therapies for pulmonary hypertension, their biologic rationales, and evidence for their clinical effectiveness.",
keywords = "Phosphodiesterase, Prostacyclin, Pulmonary hypertension, Pulmonary vasculature, Vasodilator",
author = "Porta, {Nicolas F M} and Steinhorn, {Robin H}",
year = "2012",
month = "3",
doi = "10.1016/j.clp.2011.12.006",
language = "English (US)",
volume = "39",
pages = "149--164",
journal = "Clinics in Perinatology",
issn = "0095-5108",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Pulmonary Vasodilator Therapy in the NICU

T2 - Inhaled Nitric Oxide, Sildenafil, and Other Pulmonary Vasodilating Agents

AU - Porta, Nicolas F M

AU - Steinhorn, Robin H

PY - 2012/3

Y1 - 2012/3

N2 - The perinatal transition from fetal to extrauterine life requires a dramatic change in the circulatory pattern as the organ of gas exchange switches from the placenta to the lungs. Pulmonary hypertension can occur during early newborn life, and present as early respiratory failure or as a complication of more chronic diseases, such as bronchopulmonary dysplasia. The most effective pharmacotherapeutic strategies for infants with persistent pulmonary hypertension of the newborn are directed at selective reduction of pulmonary vascular resistance. This article discusses currently available therapies for pulmonary hypertension, their biologic rationales, and evidence for their clinical effectiveness.

AB - The perinatal transition from fetal to extrauterine life requires a dramatic change in the circulatory pattern as the organ of gas exchange switches from the placenta to the lungs. Pulmonary hypertension can occur during early newborn life, and present as early respiratory failure or as a complication of more chronic diseases, such as bronchopulmonary dysplasia. The most effective pharmacotherapeutic strategies for infants with persistent pulmonary hypertension of the newborn are directed at selective reduction of pulmonary vascular resistance. This article discusses currently available therapies for pulmonary hypertension, their biologic rationales, and evidence for their clinical effectiveness.

KW - Phosphodiesterase

KW - Prostacyclin

KW - Pulmonary hypertension

KW - Pulmonary vasculature

KW - Vasodilator

UR - http://www.scopus.com/inward/record.url?scp=84857087887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857087887&partnerID=8YFLogxK

U2 - 10.1016/j.clp.2011.12.006

DO - 10.1016/j.clp.2011.12.006

M3 - Article

C2 - 22341543

AN - SCOPUS:84857087887

VL - 39

SP - 149

EP - 164

JO - Clinics in Perinatology

JF - Clinics in Perinatology

SN - 0095-5108

IS - 1

ER -